- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT07828353
A Clinical Study of REGEND001 for the Treatment of Chronic Obstructive Pulmonary Disease (COPD)
A Multicenter, Randomized, Blinded, Placebo-Controlled Confirmatory Clinical Trial of Autologous REGEND001 Cell Therapy for the Treatment of Chronic Obstructive Pulmonary Disease (COPD)
Chronic obstructive pulmonary disease (COPD) is a common, progressive, and heterogeneous respiratory disorder. It is associated with substantial morbidity and mortality worldwide, leading to progressive decline in lung function, impaired quality of life, and a significant healthcare burden. REGEND001, made from airway basal stem cells with ability to regenerate lung tissue, is promising to COPD treatment. In this study, a multicenter, randomized, blinded, placebo-parallel-controlled trial is performed to verify the efficacy and safety of REGEND001 in treatment of COPD patients with emphysema.
Studieoversikt
Status
Intervensjon / Behandling
Studietype
Registrering (Antatt)
Fase
- Fase 3
Kontakter og plasseringer
Studiekontakt
- Navn: Shiyue Li, Professor and Chief Physician
- Telefonnummer: 86-20-83062114
- E-post: lishiyue@188.com
Studiesteder
-
-
Guangdong
-
Guangzhou, Guangdong, Kina
- The First Affiliated Hospital of Guangzhou Medical University
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Male or female, aged 40-75 years;
- Diagnosed with COPD;
- Post-bronchodilator FEV1/FVC <0.7
- Emphysematous lesions demonstrated by HRCT;
- Hemoglobin-corrected DLCO%predicted ≥20% and <70%;
- Post-bronchodilator FEV1%predicted ≤80%;
- COPD Assessment Test (CAT) score ≥3;
Exclusion Criteria:
- History of ≥2 COPD exacerbations leading to hospitalization within 1 year prior to screening, or a COPD exacerbation leading to hospitalization within 2 months prior to screening;
- Current or previous history of malignancy;
- An assessed life expectancy of <1 year;
- Respiratory tract infection or systemic infection requiring treatment, or severe localized infection within 4 weeks prior to screening;
- History of invasive or non-invasive mechanical ventilation within 4 weeks prior to screening;
- Diagnosis of pneumonia within 3 months prior to screening;
- Abnormal coagulation function affecting the safety of fiberoptic bronchoscopy procedures at screening;
- Subjects requiring long-term maintenance anticoagulant therapy or antiplatelet therapy, who are unable to discontinue such medications for at least 1 week prior to cell collection and cell infusion;
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Dobbelt
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Placebo komparator: Placebo
Participants randomized to the Placebo Comparator arm will receive a single administration of placebo. |
Participants enrolled will have a bronchoscopy with brushing for cell collection, followed by a single adiministratoin of placebo via bronchoscopy and 1 year of follow-up. |
|
Eksperimentell: REGEND001
Participants randomized to the experimental arm will receive a single administration of REGEND001. |
Participants enrolled will have a bronchoscopy with brushing for cell collection, followed by a single adiministratoin of REGEND001 via bronchoscopy and 1 year of follow-up. |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Change from baseline in the measured Diffusing Capacity of the Lung for Carbon Monoxide (DLCO)
Tidsramme: Week 52 after treatment
|
The change from baseline in measured DLCO is defined as the difference between the absolute measured DLCO value at baseline and that measured at the assessment time point after treatment. |
Week 52 after treatment
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Change from baseline in COPD Assessment Test (CAT) score
Tidsramme: Week 12, 24 and 52 after treatment
|
The COPD Assessment Test (CAT) is an 8-item questionnaire used to assess the impact of COPD on health status. The total score ranges from 0 to 40, with higher scores indicating a greater impact of COPD and worse health status. Change from baseline is calculated as the post-treatment CAT score minus the baseline CAT score. |
Week 12, 24 and 52 after treatment
|
|
Proportion of subjects with a ≥2-point improvement or worsening from baseline in CAT score
Tidsramme: Week 12, 24 and 52 after treatment
|
Minimal clinically important difference for CAT is recognized as 2 points. |
Week 12, 24 and 52 after treatment
|
|
Change from baseline in DLCO
Tidsramme: Week 12, 24 and 52 after treatment
|
DLCO is assessed by absolute measured value, hemoglobin (Hb)-corrected measured/predicted ratios and corresponding area under curve (AUC). |
Week 12, 24 and 52 after treatment
|
|
Proportion of subjects with a ≥11% relative improvement or worsening from baseline in absolute measured DLCO
Tidsramme: Week 12, 24 and 52 after treatment
|
Minimal clinically important difference (MCID) of DLCO is recognized as 11%. |
Week 12, 24 and 52 after treatment
|
|
Change from baseline in alveolar volume (VA)
Tidsramme: Week 12, 24 and 52 after treatment
|
VA is assessed by measured values, measured/predicted ratio and corresponding area under curve (AUC). |
Week 12, 24 and 52 after treatment
|
|
Change from baseline in forced expiratory volume in the first second (FEV1) post-bronchodilator
Tidsramme: Week 12, 24 and 52 after treatment
|
FEV1 is assessed by measured value, measured/predicted ratio and corresponding area under curve (AUC). |
Week 12, 24 and 52 after treatment
|
|
Change from baseline in 6-minute walk distance (6MWD)
Tidsramme: Week 12, 24 and 52 after treatment
|
6MWD is assessed by the measured value and corresponding area under curve |
Week 12, 24 and 52 after treatment
|
|
Proportion of subjects with a ≥30-meter change from baseline in 6MWD
Tidsramme: Week 12, 24 and 52 after treatment
|
Minimal clinically important difference (MCID) of 6MWD is recognized as 30 meters. |
Week 12, 24 and 52 after treatment
|
|
Change from baseline in St. George's Respiratory Questionnaire for COPD (SGRQ-C) score
Tidsramme: Week 12, 24 and 52 after treatment
|
The St. George's Respiratory Questionnaire for COPD (SGRQ-C) is a validated disease-specific patient-reported outcome measure used to assess the impact of COPD on patients' health status and quality of life. Total score, ranged from 0 to 100, is the sum of points from all items. A higher value represents a worse outcome. |
Week 12, 24 and 52 after treatment
|
|
Proportion of subjects with a ≥4-point improvement or worsening from baseline in SGRQ-C score
Tidsramme: Week 12, 24 and 52 after treatment
|
Minimal clinically important difference for SGRQ is recognized as 4 points. |
Week 12, 24 and 52 after treatment
|
|
Annualized rate of COPD exacerbations (AECOPD), adjusted for prior exacerbation history and baseline characteristics
Tidsramme: Week 52 after treatment
|
The annualized rate of COPD exacerbations (AECOPD), adjusted for prior exacerbation history and baseline characteristics, represents the adjusted frequency of acute exacerbations of COPD over the assessment period. |
Week 52 after treatment
|
|
Change from baseline in arterial blood gas parameters
Tidsramme: Week 52 after treatment
|
The change from baseline in arterial blood gas parameters reflects changes in gas exchange function and respiratory status over the assessment period. |
Week 52 after treatment
|
|
Change from baseline in HRCT images
Tidsramme: Week 52 after treatment
|
HRCT images are quantitatively analyzed using dedicated software to measure emphysema volume (mL) and functional lung volume (mL). |
Week 52 after treatment
|
|
Adverse Event
Tidsramme: Hour 24, Week 12, 24 and 52 after treatment
|
An adverse event (AE) is any untoward medical occurrence in a subject who has received a study intervention, regardless of whether or not it is considered related to the intervention. |
Hour 24, Week 12, 24 and 52 after treatment
|
Samarbeidspartnere og etterforskere
Sponsor
Studierekorddatoer
Studer hoveddatoer
Studiestart (Antatt)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- REGEND001-COPD-251
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .